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Background: Ongoing clinical trials, in regenerative therapy of patients suffering from myocardial infarctions, rely
primarily upon administration of bone marrow stem cells to the infarcted zones. Unfortunately, low retention of
these cells, to the therapeutic delivery sites, reduces effectiveness of this strategy; thus it has been identified as the
most critical problem for advancement of cardiac regenerative medicine.
Specific aims: The specific aim of this work was three-fold: (1) to isolate highly viable populations of human,
autologous CD34+, CD117+, and CD133+ bone marrow stem cells; (2) to bioengineer heterospecific, tetravalent
antibodies and to use them for recruiting of the stem cells to regenerated zones of infarcted myocardium; (3) to
direct vasculogenesis of the retained stem cells with the defined factors.
Patients methods: Cardiac tissue was biopsied from the hearts of the patients, who were receiving orthotopic
heart transplants after multiple cardiac infarctions. This tissue was used to engineer fully human in vitro models
of infarcted myocardium. Bone marrow was acquired from these patients. The marrow cells were sorted into
populations of cells displaying CD34, CD117, and CD133. Heterospecific, tetravalent antibodies were bioengineered
to bridge CD34, CD117, CD133 displayed on the stem cells with cardiac myosin of the infarcted myocardium. The
sorted stem cells were administered to the infarcted myocardium in the in vitro models.
Results: Administration of the bioengineered, heterospecific antibodies preceding administration of the stem cells
greatly improved the stem cells’ recruitment and retention to the infarcted myocardium. Treatment of the retained
stem cells with vascular endothelial growth factor and angiopoietin efficiently directed their differentiation into
endothelial cells, which expressed vascular endothelial cadherin, platelet/endothelial cell adhesion molecule,
claudin, and occludin, while forming tight and adherens junctions.
Conclusions: This novel strategy improved retention of the patients’ autologous bone marrow cells to the infarcted
myocardium followed by directed vasculogenesis. Therefore, it is worth pursuing it in support of the ongoing
clinical trials of cardiac regenerative therapy.
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Myocardial infarctions result from occlusion of cardiac
arteries leading to cessation of the heart’s blood supply,
what causes necrosis of the cardiac muscle [1-3]. Cardiac
and bone marrow stem cells are mobilized as natural
healing response to the infarction [4-8]. That response
may be enhanced by stimulation with pharmaceuticals
or transgenes [9-12]. Unfortunately, those remedies
may not be sufficient. Hence, the rationale for stem cell
therapy is to boost processes of cardiac regeneration by
supplying stem cells, which have to differentiate into
cardiac cells in order to replace necrotic cells and to
restore lost cardiac functions [13-17].
For the ongoing stem cell therapy clinical trials of cardiac
regeneration, bone marrow and heart are the primary
sources of the stem cells. Cardiac stem cells are more
advanced in specialization toward cardiomyocytes, but
they require surgery for acquisition and time for in vitro
expansion [18,19]. On the other hand, bone marrow is
easily aspirated and instantly ready for administration
in GMP regimes [20-25]. However, reported outcomes
of these trials are inconsistent. Interpretations of the
results’ variability include, but are not limited to, differ-
ences in: cell isolation and propagation procedures,
viability of cells in therapeutic batches, purity of the
cell batches with undetermined numbers of apoptotic/
necrotic cells, numbers of administered cells, ways of
monitoring numbers of cells recruited and retained to
the therapeutic targets, incompatibility of the human stem
cell biomarkers with those of non-humans determined
in pre-clinical experiments, routes of the cells’ delivery,
heterogeneity of marrow cells’ populations, and admin-
istration of unfractionated vs selected cell populations.
The clinical trials in cardiac regeneration, using bone
marrow enriched with populations of cells displaying
CD34, CD117, and CD133, have been reported as most
successful [19,22-27]. Those reports match laboratory
research data, which highlight cell surface expression of
these biomarkers on human endothelial or myocardial
progenitors [28-34].
The main mechanisms contributing to the stem cell
based cardiac regeneration include: paracrine stimulation,
cell fusion, and trans-differentiation [35,36]. Nevertheless,
in all these scenarios, the stem cells have to be delivered
and retained to the treated tissues in sufficient numbers
to attain therapeutic effects. Unfortunately, within 2 weeks,
only 3-6% of the stem cells administered by infusion, or
6-12% of those administered by intramyocardial injection,
remain detected at the sites of therapeutic interventions
[13,14,37,38]. This problem dramatically reduces therapeutic
efficacy. Therefore, improving retention of the administered
stem cells to the sites of therapeutic interventions has
been recognized, as the most critical problem to resolve
for improving efficacy of stem cell therapy [13,37,38].To be retained, migrating and administered stem cells
require solid scaffolds, within infarcted zones, to anchor
onto. Upon infarction, the myocardial sarcolemmas are
damaged. Some of the sarcomeric molecules are very
quickly released to blood circulation, e.g., troponin, or
light chains of myosin. Measuring their levels helps us to
determine magnitudes of infarctions. The other molecules
remain strongly incorporated into the architecture of
sarcomeres, e.g., myosin heavy chains. Importantly, cardiac
myosin also retains its antigenicity. Therefore, labeling
with anti-myosin antibodies, modified with radioactive
or superparamagnetic biotags, helps us to determine
location and extent of infarction with PET or MRI.
Therefore, cardiac myosin heavy chains are the most
specific and stable structures in the infarcted zones to
anchor the stem cells onto.
Equally important requirement for successful stem cell
therapy is administration of cell batches with exquisite
purity and excellent viability [38,39]. This can be accom-
plished by thorough depletion of necrotic and apoptotic
cells [40], as well as definite enrichment of selected
batches with the aid of bioengineered fluorescent anti-
bodies for gentle isolation by fluorescent activated cell
sorting (FACS) at low rates with reduced pressure or
superparamagnetic antibodies for magnetic activated cell
sorting (MACS) at low field gradient [41-46].
The specific aim of this work was three-fold: (1) to
isolate highly viable populations of human, autologous
CD34+, CD117+, and CD133+ bone marrow stem cells;
(2) to bioengineer heterospecific, tetravalent antibodies
and to use them for recruiting of the stem cells to regener-
ated zones of infarcted myocardium; (3) to direct vasculo-
genesis of the retained stem cells with the defined factors.
Methods
Concept of novel strategy for cardiac regeneration with
human autologous bone marrow cells
Novel strategy for recruitment and retention of the human,
autologous, bone marrow stem cells (haBMSC) to the
sarcomeres of the infarcted myocardia with the aid of the
heterospecific, tetravalent antibodies (htAbs) is illustrated
(Figure 1).
The foundation for this strategy was bioengineering
of the htAbs. For this purpose, the monovalent nano-
antibodies, each targeting CD34, CD117, CD133, and
MHC, were modified to carry the single biotin group at
their carboxyl termini. One at a time, these antibodies
were docked into avidin, thus forming sequentially
mono-, bi-, tri-, or tetra-valent antibodies. Since each
of the four, incorporated, monovalent nano-antibodies
was different, then the final antibody was the htAb.
Therefore, these htAbs worked as the bridges between
myosin in sarcomeres of the infarcted myocardium
and CD34, CD117, CD133 displayed on surfaces of the
Figure 1 Concept of novel strategy for cardiac regeneration with human autologous bone marrow cells. (A) Heterospecific, tetravalent
antibodies (htAbs) contain binding domains for four different antigens: CD34, CD117, CD133, and myosin. They are injected into the solution
flowing over the sarcomeres of the infarcted myocardium. (B) The htAbs dock onto myosins of the sarcomeres. Excess of the htAbs is cleared
from the circulation. (C) Human, autologous, bone marrow stem cells (haBMSCs) are spiked into the solution. (D) The cells displaying on their
surfaces CD34, CD117, CD133 are recruited and retained to the infarcted myocardium sarcomeres with the aid of the htAbs (only CD117 cell is
shown here for clarity). The retained haBMSCs are directed to differentiate into endothelium with the defined factors (not shown).
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(haBMSCs).
Five steps were involved in pursuit of this strategy: (A)
administration of htAbs; (B) recruitment of the htAbs
onto the myocardial sarcomeric myosin; (C) administration
of haBMSCs; (D) recruitment of the haBMSCs onto the
anchored htAbs; (E) directed differentiation of the re-
cruited haBMSCs into endothelium. In vitro simulation
of this therapeutic strategy is described below.
Patients, cardiac tissue, bone marrow
All the samples were acquired in accordance with the
Declaration of Helsinki with the Patients’ Informed Con-
sent and with the Institutional Review Boards’ approval.
Bone marrow aspirates were acquired from six patients
receiving orthotopic heart transplants. The surgical pro-
cedures were performed in the sterile conditions after
induction of general anesthesia. Using heparinized, sterile
needles, approximately 10 ml volumes of bone marrow
were aspirated from the iliac crests. No iatrogenic com-
plications were ever reported.
Populations of the desired cells were isolated directly
from the bone marrow aspirates. They were labeled with
the bioengineered antibodies targeting CD34, CD117,
and CD133 as described earlier [34,40]. The antibodies
were rendered fluorescent or superparamagnetic [40].
These antibodies were applied at the concentration of
0.01 pg of antibody/1 × 10^4 cells for 30 min at 4°C
on ice in darkness, while rocked on gyroscopic tables.
The isotype nano-antibodies were used as the controls.
The fluorescent or superparamagnetic antibodies, against
double stranded DNA and phosphatidylserine, were usedto remove necrotic or apoptotic (respectively) cells.
The yields varied, but the cell numbers were reaching
1 × 10^4 – 2 × 10^10^6 per sample. Three rounds of
isolations were pursued. The isolated cells were further
analyzed by flow cytometry or lysed for the native recep-
tors immuno-magnetic precipitation, electrophoresis, and
blotting as described [40].
The cardiac tissues were obtained from the hearts of
the recipients of heart transplants in orthotopic procedures.
Immediately after the hearts were released during the
open chest surgery, they were immersed into the ice-cold
University of Wisconsin solution and the samples were ex-
cised from the central zone of the infarcted myocardium.
Thereafter, the cardiac samples were prepared as: (1) myo-
fibrils; (2) sections; (3) cryo-mounts; (4) primary cultures;
(5) homogenates.
Strips of the cardiac muscle tissue were brought to a
stretched or contracted state and clamped with the U
shaped vascular surgery forceps. They were immersed in
the solution (75 mM KCI, 10 mM Tris pH6.8, 2 mM
EGTA, 2 mM MgCl2, 0.1 mM PMSF, 0.1% Triton X-100).
The tissues were homogenized in a Polytron (Brinkman
Instruments Co., Westbury, NY, USA) and a Teflon glass
homogenizer. Myofibrils were collected by centrifugation
at 1,000 g for 5 min. The pellets were washed by cycles
of re-suspension and centrifugation. Finally, they were
infused with the fresh buffer containing 50% glycerol
and frozen at −20°C for storage. They were thawed and
rinsed with the fresh buffer before use.
Cardiac tissues were rapidly cryoimmobilized in the
HPM 010 (Balzers, Lichtenstein, EU). The frozen muscles
were either sectioned in the frozen hydrated state or cryo-
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sectioned on the cryoultramicrotome (Leica, Vienna, A,
EU). Alternatively, the frozen tissues were crushed for
homogenates.
Small cubes of the fresh cardiac tissues were disinte-
grated with the sterile, surgical scalpel and plated onto
the Petri dishes with the bottoms covered by matrigel or
native cardiac tissue sections and filled with the DMEM
supplemented with serum, powdered cardiac tissues,
and antibiotics. The primary cultures were grown in the
incubators maintaining 37°C, 10% CO2, and saturated
humidity. For storage, the tissue cultures were infused
with DMSO or glycerol and frozen gradually to retain
their viability.
The cryoimmobilized samples were crushed, frozen,
and lyophilized. They were used after rehydration as
the media supplement or studied by electrophoresis
and blotting.
All these approaches assured preservation of the native
state of the cardiac muscle protein antigenicity and archi-
tecture. All specimens were examined by flow cytometry
(FCM), multiphoton fluorescence spectroscopy (MFS),
nuclear magnetic resonance spectroscopy (NMRS), energy
dispersive x-ray spectroscopy (EDXS) [38,45].
Bioengineering of heterospecific, tetravalent antibodies
Heterospecific, tetravalent antibodies were bioengineered
as described [45]. Briefly, the B cells were isolated from
the blood of patients suffering cancers and myocardial
infarctions. The pooled B cells from these patients were
used to isolate mRNA, which was reverse transcribed to
create the human cDNA libraries. The cds, after insertion
into the plasmids containing chelates’ harboring coding
sequences under the CMV promoters and terminated
with polyA, were propagated and expressed in human
myelomas or B cells. Gene shuffling enhanced the libraries’
diversities. The native CD34, CD117, CD133 were purified
by immunoprecipitation with antibodies, which followed by
their modification with biotin, digoxigenin, or fluorescein.
They were anchored onto anti-biotin, anti- digoxigenin, or
anti- fluorescein saturated pans and served as baits for
selection of the expression libraries. The chelates were
saturated with Gd, Tb, Ru, and Eu. The specificity and
sensitivity were determined based upon elemental compo-
sitions with EDXS (Noran, Middleton, WI, USA), EELS
(Zeiss, Oberkochen, D, EU), or TRXFS (Bruker AXS,
Fitchburg, WI, USA). The fluorescent properties were mea-
sured with the RF-5301PC spectrofluorometer (Shimadzu,
Tokyo, Japan). The magnetic relaxivities were measured on
the DMX 400 WB or AVANCE II NMR spectrometers
(Bruker Optics, Dallas, TX, USA).
For preparing tetravalent antibodies, the first batch of
the bioengineered, monovalent antibodies was sprayed
from an air-brush with a single pulse over the pan filledwith the 0.001 mg/mL recombinant avidin (rA) in PIPES
buffer in a saturated humidity chamber maintained at
room temperature. Upon complete binding, the fractions
of resulting solution were separated by the size exclusion
chromatography on the high pressure liquid chromatog-
raphy (HPLC) (Pharmacia, S, EU) columns. The fractions
were collected on the fraction collector (Pharmacia, S,
EU). The fractions detected to contain rA linked with the
single monovalent antibody were pooled together and
sprayed over the new pan. The procedure was repeated
for all the antibodies, one at a time, in a random order.
The system was calibrated using peaks for classic IgG,
Fab, Fc, and avidin, as the references.
Fluorescent, activated cell sorting. Flow cytometry.
Multiphoton fluorescence spectroscopy
The marrow cells were labeled with the fluorescent, bioen-
gineered antibodies targeting CD34, CD117, and CD133
and for negative selection with the antibodies targeting
double stranded DNA (dsDNA) and phosphatidylserine
(PS) in a single step at 4°C in darkness for 30 minutes
[40]. They were sorted on the Calibur, Vantage SE, or Aria
(Becton-Dickinson, Franklin Lakes, NJ, USA). The anti-
bodies were dissolved and all washing steps carried in
phenol-free, Ca+/Mg+- free, PIPES buffered saline solution,
supplemented with 20 mM glucose, 5% human serum. The
labeled marrow cells were sorted on Aria, Calibur, Vantage
SE (Becton-Dickinson, Franklin Lakes, NJ, USA) with the
sheath pressure set at 20 pounds per square inch pressure
and low count rate. The sorted batches were analyzed on
Calibur or Aria using FACSDiva software or on the FC500
(Beckman-Coulter, Brea, CA, USA). For the measurement
of the fluorescently labeled cells, these settings were tuned
at the maximum emission for the Eu chelated antibody
at 500 V with references to isotype antibodies and non-
labeled cells. This assured the comparisons between
populations of cells labeled with multiple antibodies
without changing the settings on PMTs.
The fluorescently labeled cells or tissues were imaged
with the Axiovert (Zeiss, Oberkochen, D, EU) equipped
with the Enterprise argon ion (457 nm, 488 nm, 529 nm
lines) and ultraviolet (UV) (364 nm line) lasers; Odyssey
XL digital high-sensitivity with instant deconvolution
confocal laser scanning imaging system operated up to
240 frames/s (Noran, Madison, WI, USA), and the Diaphot
(Nikon, Tokyo, Japan) equipped with the Microlase
diode-pumped Nd:YLF solid state laser (1048 nm line)
(the multi-photon fluorescence station built based upon
the NIH funds – Principal Investigator: Dr J. White).
Nuclear magnetic resonance spectroscopy. Magnetic
activated cell sorting
The marrow cells were labeled for positive selection with
the superparamagnetic nano-antibodies targeting CD34,
Malecki et al. Molecular and Cellular Therapies 2013, 1:4 Page 5 of 13
http://www.molcelltherapies.com/content/1/1/4CD117, CD133, and for negative selection with the
antibodies targeting double stranded DNA (dsDNA)
and phosphatidylserine (PS) [40]. The antibodies were
dissolved and all washing steps carried in phenol-free,
Ca+/Mg+- free, PIPES buffered saline solution, supple-
mented with 20 mM glucose, 5% human serum. The
aliquots were dispensed into the magnetism-free NMR
tubes (Shigemi, Tokyo, Japan). The relaxation times T1
were measured in resonance to the applied pulse sequences
on the NMR spectrometers: DMX 400 WB or AVANCE II
NMR (Bruker, Billerica, MA) or the Signa clinical scanners
(GE, Milwaukee, WI, USA).
The superparamagnetic nano-antibodies were also used
to isolate the labeled cells from the solution. The marrow
cells labeled with the superparamagnetic antibodies were
isolated on the magnetic, activated cell sorter operated at
1.5 T (the superparamagnetic bioengineered antibodies
and sorter designed and built based upon the NSF funds –
Principal Investigator: Dr M. Malecki).Energy dispersive X-ray spectroscopy. X-ray reflection
fluorescence spectroscopy
The samples, which were cryo-immobilized, presented
the life-like antigenicity and supramolecular organization.
Elemental analyses were pursued by EDXS and XRFS as
described [40]. The field emission, scanning transmission,
electron microscope FESTEM HB501 (Vacuum Generators,
Kirkland, WA, USA) was equipped with the energy disper-
sive x-ray spectrometer (EDXS) (Noran, Middleton, WI,
USA) and post-column electron energy loss spectrometer
(EELS) (Gatan, Pleasanton, CA). The cryo-energy filtering
transmission electron microscope 912 Omega was equipped
with the in-column, electron energy loss spectrometer
(EELS) and the energy dispersive x-ray spectrometer
(EDXS) (Zeiss, Oberkochen, D, EU). The cryo-energy
filtering transmission electron microscopes 410 and 430
Phillips were equipped with the post-column, electron
energy loss spectrometers (EELS) and the energy disper-
sive x-ray spectrometer (EDXS) (Noran, Middleton, WI,
USA). The field emission, scanning electron microscope
SEM1530 (Zeiss, Oberkochen, D, EU) was equipped with
the energy dispersive x-ray spectrometer (EDXS) (Noran,
Middleton, WI, USA). The field emission, scanning electron
microscope 3400 was equipped with the energy dispersive
x-ray spectrometer (EDXS) (Hitachi, Tokyo, Japan). The
S2 Picofox XRFS spectrometer was equipped with a
molybdenum (Mo) X-ray target and the Peltier cooled
Xflash Silicon Drift Detector (Bruker AXS, Fitchburg,
WI, USA). Scan times ranged up to 1000 seconds. The
ICP standard of 1000 mg/l of mono-element Gallium
or Gadolinium (CPI International, Denver, CO, USA) was
added to 500 microL of each sample to the final concen-
tration of 10 mg/l. Instrument control, data collection,and analysis were under the SPECTRA 7 software (Bruker
AXS, Fitchburg, WI, USA).
Quantitative reverse transcription and polymerase
chain reaction
Total RNA was isolated with TRIzol (MRC, Cincinnati,
OH, USA). RNA served as the template to generate cDNA
through reverse transcription using random hexamers and
reverse transcriptase (ABI, Foster City, CA, USA). The
transcripts for GAPDH and actin served as the controls
(ABI, Foster City, CA, USA). They were synthesized on
the 380A DNA Synthesizer (ABI, Foster City, CA, USA).
The PCR reactions were carried using the mix of the
cDNA, the synthesized primers, dNTPs, and Taq DNA
polymerase (Hoffmann–La Roche, Basel, H) on the Robo-
cycler (Stratagene, San Diego, CA, USA), Mastercycler
(Eppendorf, Hamburg, D, EU), and 7500 or 7900 systems
(ABI, Foster City, CA, USA). The images of the electro-
phoresed amplicons were acquired and quantified with
Fluoroimager (Molecular Dynamics, Sunnyvale, CA, USA)
or Storm 840 (Amersham, Buckinghamshire, UK, EU).
The levels of the transcripts were all normalized against
GAPDH or actin. Thereafter, they were calculated as
the ratios between the transcripts’ concentration in the
examined patient’s cells versus the cells from the healthy
control tissues and cultures.
Immunoblotting
The cells and tissues were either frozen and crushed or
disintegrated with ultrasonicator (Branson Ultrasonic,
Danbury, CT, USA) and homogenized within the sample
buffer. They were stored in liquid nitrogen. They were
electrophoresed in the native buffer (Invitrogen, Carlsbad,
CA, USA). They were vacuum- or electro-transferred onto
the PVDF membranes (Amersham, Buckinghamshire, UK,
EU). The membranes carrying the transferred proteins
were first soaked within human serum and thereafter
labeled with the bioengineered antibodies. The purified
CD34, CD117, CD133, and cardiac muscle myosin
served as the controls. The images of the blots were
acquired and quantified with Fluoroimager (Molecular
Dynamics, Sunnyvale, CA, USA) or Storm 840 (Amersham,
Buckinghamshire, UK, EU).
Targeting and retention of the human, bone marrow
stem cells
The chambers were filled with cardiac tissues and tightly
sealed. Solutions were propelled to flow through the
chambers by the peristaltic pump (Flowrox, Linthicum,
MD, USA). The chambers were connected with the
environmental incubator through flexible Tygon hoses.
That assured maintaining of the sarcomeres and the
bone marrow cells at 37°C, pH 7.3, 120/80 mmHg, and
330 mOsm. Cardiac α-actinin of sarcomeres was labeled
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references. The cells were tagged with fluorescent of
superparamagnetic or fluorescent antibodies. Under the
continuous flow, the bone marrow stem cells were
administered. At various time intervals, the flow was
stopped and the number of the retained stem cells
quantified based upon the changes in ratios of fluores-
cence or relaxivity.
Directing vasculogenesis of the stem cells retained
to sarcomeres
Upon completion of the recruitment of the bone mar-
row stem cells to the cardiac tissues, the solution,
flowing through the chambers, was Vascular Cell Basal
Medium (ATCC, Arlington, VA, USA) supplemented
with recombinant human Vascular Endothelial Growth
Factor 50 ng/mL, recombinant human Epidermal Growth
Factor 5 ng/mL, recombinant human Basic Fibroblast
Growth Factor 5 ng/mL, recombinant human Insulin-like
Growth Factor 15 ng/mL, angiopoietin-1 20 ng/mL, L-
glutamine 10 mM, heparin sulfate 0.75 Units/mL, hydro-
cortisone hemisuccinate 1 μg/mL, ascorbic acid 50 μg/mL.
At various time intervals, endothelial differentiation
was validated by monitoring expression of the uniquely
specific genes: TJP1 for zona occludens; OCLN5 for
endothelial occludin; CLDN5 for endothelial claudin;
PECAM1 for platelet/endothelial cell adhesion molecule
1; CTNNB for catenin cadherin-associated protein; and
CDH5 for vascular endothelium cadherin 5. For imaging,
fluorometry, and flow cytometry, these genes were ex-
pressed as fusions with green fluorescent protein (GFP)
and its mutations blue, yellow, cyan, orange, and red
and gene expression products were labeled with nano-
antibodies [40-46]. Human Normal Primary Artery
Endothelial Cells served as the positive and Human
Bone Marrow served as the negative controls (ATCC,
Arlington, VA, USA). Imaging, blotting, and amplification
were pursued as outlined below.
Statistical analysis
All the measurements were run in triplicates for each
sample from six patients (three women and three men).
The numbers were analyzed and displayed using GraphPad
software (GraphPad Software, Inc, La Jolla, CA). Data
were presented as mean ± standard error of the mean
(SEM). Statistical significance was calculated by t-test
for two groups.
Results
To assess preservation of the architecture and antigenic-
ity of myosin in infarcted myocardia, which were both
critical for anchoring human autologous bone marrow
stem cells (haBMSCs), the sarcomeres were studied bymultiphoton fluorescence spectroscopy and immuno-
blotting, while the results are illustrated (Figure 2).
The overall structure of the native myofibril sarcomeres
is shown in the Zernicke’s phase contrast. A-bands and
Z-lines are well preserved with sharp edges and no deteri-
oration of architecture. The A-bands constitute majority
of the sarcomeres’ volume; thus the largest binding surface
for antibodies intended to dock onto sarcomeres. Projec-
tion of the myosin labeling pattern onto the myofibrils
shows exact overlapping with the A-band. There is ab-
sence of non-specific labeling in the background. All the
samples were run in triplicates. The images of sarcomeres
from the tissue biopsied from this patient’s heart were
representative for all samples studied. It is indicative of
myosin’s preserved antigenicity, which is the critical
feature for specific binding of the htAbs.
Preservation of sarcomeric proteins was demonstrated
by electrophoresis. It revealed sharp bands in the classical
pattern of cardiac muscle proteins in all the patients’
samples. Prominent bands of myosin, as well as bands of
actin, actinin, and tropomyosin are clearly distinguished.
The myosin labeling patterns after electro-transfer and
immunoblotting can be projected onto the lanes of the
electrophoresed cardiac muscle. The bands corresponding
to myosin are heavily labeled with the htAbs. All the
samples were run in triplicates. The myosin blot pat-
tern revealed on the biopsy from these patients were
representative for all samples studied. The labeling is
very specific, which is critical for using the htAbs for
recruiting the haBMSCs.
To test purity and viability of isolated populations of
bone marrow cells, they were analyzed by flow cytometry
(Figure 3). The batches of these cells featured exquisite
purity. Negative selection with the antibodies against
double stranded DNA (anti-dsDNA) and phosphatidyl-
serine (anti-PS) ensured absence of dead and apoptotic/
dying cells; thus assured high viability of the haBMSCs
planned for being used for stem cell therapy. All the
samples were run in triplicates and shown patterns
were representative for all studied.
To validate purity of the isolated batches of stem cells
after rounds of sorting, the batches of stem cells were
tested by electrophoresis and immunoblotting. Purified
CD34, CD117, CD133 were used as the positive controls.
All the samples were run in triplicates. The immunoblot-
ting patterns revealed on these samples were representative
for all studied. The labeling is uniquely specific for the
CD34, CD117, CD133, as validated by the identical
bands of labeling on the lanes carrying lysates of the
batches of the haBMSCs, as on the lanes carrying only
the purified receptors as the specificity controls. There
were neither other cells detected, nor any other molecules
labeled, but the ones specifically displaying biomarkers
targeted by the htAbs.
Figure 2 (See legend on next page.)
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Figure 2 Preservation of architecture and antigenicity of myosin in infarcted myocardia. (A) The Zernicke’s phase-contrast microscopy
showed the overall structure of the sarcomeres in the human, native, cardiac myofibrils from the central zone of infarcted myocardium. (B) Cardiac
myosin (in the sarcomeres of the myofibrils from A) was labeled with the fluorescent htAbs against myosin and highlighted in multiphoton fluorescence
spectroscopy. The anti-myosin htAbs overlap exactly the A-bands of the sarcomeres. (C) Gels of the four patients' (MI/HT001-004) cardiac tissues, which
were disintegrated, electrophoresed, and stained, revealed prominent and sharp bands of myosin, actin, tropomyosin, troponin, actinin, and titin. These
show preservation of molecular integrity of the sarcomeric proteins. (D) The same samples as those shown in C, were transferred onto PVDF membranes,
and labeled with the htAbs against myosin. The only bands are exquisitely specific for the labeled myosin. These are also indications of preservation
of myosin antigenicity. The entire lanes are shown to demonstrate very specific labeling and lack of any non-specific binding. Axial pixel brightness
compared between specific signals and backgrounds was accepted at P = .0003.
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of the haBMSCs to the infarcted myocardial sarcomeres,
is summarized (Figure 4). In all the assays, injections of
the haBMSCs were preceded by injections of: either the
htAbs, or blocking antibodies, or blocking ligands, or
non-specific antibodies, or plain buffers with no anti-
bodies. Quantification was performed with the energy
dispersive x-ray spectroscopy (EDXS), x-ray fluorescence
spectroscopy (XRFS), or nuclear magnetic resonance
spectroscopy (NMRS). Permanent labeling of the haBMSCs
with elemental biotags facilitated measurements of emitted
x-ray radiation by EDXS and XRFS, which was proportionalFigure 3 Purity and viability of isolated, human, autologous, bone ma
superparamagnetic htAbs targeting CD34 (A), CD117 (B), CD133 (C) and sorti
antibodies against double stranded-DNA (anti-dsDNA) and apoptotic – labele
out entirely so are not detected by flow cytometry (empty Q4). The counts w
was further assessed on immunoblots. Isolated populations of haBMSCs (BMS
homogenized and lysed. They were electrophoresed on parallel lanes to purif
samples were transferred onto PVDF membranes and labeled with the htAbs
presence of the only cells displaying the targeted receptors. Since there were
of other receptors, thus no falsely positive cells in these batches.to the number of cells retained. Labeling with superpara-
magnetic biotags promoted measurements of relaxivities
by NMRS. The quantification was normalized against the
total myocardial tissue mass.
Efficacy of the htAb-aided recruitment was quantified
either for the total number of bone marrow cells mixed
together or separately for populations of the isolated
CD34+, CD117+, and CD133+ cell batches. Total percent-
ages of the anchored cells were exceeding 80%. In the
mixtures of three cell populations, the ratios between
the cells anchored were approximately the same as the
ratios between the cells administered. The data collectedrrow stem cells (haBMSCs). (A-C) Batch purity after labeling with the
ng by MACS was assessed by flow cytometry. Dead cells – labeled with
d with antibodies against phosphatidylserine (anti-PS) cells were sorted
ere averaged and normalized against first 1000 events. (D-F) Batch purity
C CD34, BMSC CD117, BMSC CD133) and heart tissues (heart mf) were
ied clusters of differentiation (CD34, CD117, CD133). All electrophoresed
targeting CD34 (D), CD117 (E), CD133 (F). The immunoblots revealed
no other bands on the blots, then there was no false positive labeling
Figure 4 Recruitment and retention of haBMSCs to infarcted myocardia. (A) The isolated populations of cells with the cell surface display of
CD34, CD117, CD133 (each tagged with a different elemental tag) were applied either as a single batch of haBMSCs mixed with clusters of
differentiation saturating remaining binding sites (e.g., haBMSCs CD34+ with CD117, CD133) or as a mix of all three populations in equal ratios.
They were compared to the assay in which the haBMSCs were applied without preceding htAbs (“C” in this figure). Applying all three native
receptors blocked binding sites on the htAbs and prevented the haBMSCs from docking. The statistical significance was accepted at P = .0003.
(B) Retention of the haBMSCs onto the sarcomeres was measured at different periods of time for samples maintained in the environmental
incubator. The difference between the numbers of cells retained to the sarcomeres, when they were preceded by administration of the htAbs
(htAb) was much higher than preceded by administration of plain buffer with no antibodies (no Ab). Once the haBMSCs anchored to the
sarcomeres on the day one of the experiment (1d) , thereafter they were retained with minimal losses for up to 12 days studied (12d). The
statistical significance was accepted at P = .0003. (C) Specificity of recruitment of the CD34+, CD117+, CD133+ haBMSCs’ populations was
determined after mixing them in equal ratios and administration to myocardial infarction models, while preceded by injections of the htAbs
(htAb), non-specific antibodies (nsAbs), or plain buffer without any antibodies (no Ab). In the assays, which included htAbs, the numbers of the
cells attached were much higher, totaling more than 80%, in comparison with the assays including non-specific or excluding all antibodies. The
statistically significant difference was accepted at P = .0003.
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for all the patients as mean with standard deviations.
These measurements revealed the statistically significant
improvement in recruitment of the haBMSCs with the
aid of the htAbs as compared to the assays without the
htAbs or non-specific Abs.
Binding was very specific, as demonstrated by the
counts of the cells attached to the sarcomeres, when
the binding sites for the htAbs were selectively blocked
either on the sarcomeres with anti-myosin antibodies or
on the haBMSCs with anti-CD34, CD117, and CD133
antibodies. Selective blocking of the binding sites on the
htAbs with the ligands resulted in the reduced recruitment
of the corresponding haBMSCs’ fractions.
Retention of the recruited haBMSCs was measured
at different time intervals. Only minimal losses of the
anchored cells were measured in experiments lasting
for up to two weeks. During those periods of time, the
cells demonstrated high viability of the retained cells,
as determined by labeling with the superparamagnetic
or element tagged antibodies against double stranded
DNA (anti-dsDNA) and phosphatidylserine (anti-PS).
Ultimately, the results of this work were intended to
enhance efficacy of cardiac regeneration therapy by
directed neo-vascularization of the infarcted zones.
Therefore, the primary task for this project was to
stimulate vasculogenesis of the haBMSCs anchored to
myocardia. This was accomplished by treating thehaBMSCs retained to the sarcomeres with the vascular
endothelial growth factor (VEGF) and angipoietin-1
(Ang-1). These factors efficiently triggered expression
of genes unique for angiogenesis.
To assess the functional features of human bone marrow
cells, which were directed to differentiate into endothe-
lium, while discriminating between them and cells already
present in the myocardial tissue, transgenic expression of
fusion proteins as reporters was studied (Figure 5). Func-
tionality of endothelium is contingent upon formation of
intercellular junctions. Therefore, this work was focused
on studies of gene expression products - proteins, which
are responsible for forming tight junctions: occludin and
claudin, as well as adherens junctions: vascular endothelial
cadherin and platelet/endothelium adhesion molecules.
These proteins were imaged with the high speed, high sen-
sitivity, high spectral resolution confocal system, which was
capable to detect low intensity fluorescence and to discrim-
inate small wave-length shifts, while compensating for pos-
sible frictions of cardiac tissues and administered cells
during acquisitions of images. For each patient, the images
were acquired in triplicates and the ones presented are
representative to all. The tight junctions and adherens
junctions were effectively formed, while highlighted.
Discussion
The results of this work constitute the proof of concept,
in the fully human in vitro model, for resolving the most
Figure 5 Directed vasculogenesis of haBMSCs retained to infarcted myocardium. Vasculogenesis was assessed by monitoring expression of
the unique genes leading to assembly of tight junctions (A-C) and adherens junctions (D-F). These phenomena were highlighted by transgenic
expression of fluorescent-junction fusion proteins and fluorescent nano-antibody labeling of junction proteins (intermittent with photobleaching),
while images were acquired on high-speed, high sensitivity confocal system and followed by instant deconvolution to eliminate spectral overlaps
and resonance energy transfers, as described and validated [40,45]. Labels are: occludin (A - blue), claudin (B - cyan), zona occludens (C- green),
VE cadherin (D - yellow), catenin (E – orange), platelet/endothelial cell adhesion molecule (E – red). The colors are assigned artificially, but
correspond to wave-lengths of the narrow band-width optical filters. Unique “cobble stone” geometry of the haBMSCs directly differentiated into
endothelium is revealed.
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infarctions: recruitment and retention of the stem cells
to the sites of therapeutic interventions [13]. Herein, we
describe resolution of this problem by bioengineering of
heterospecific, tetravalent antibodies (htAbs) and using
them for recruitment and retention of selected popula-
tions of bone marrow stem cells to infarcted myocardium.
We attribute high efficacy of the htAbs, in anchoring
of the bone marrow stem cells to the human cardiac
infarcted muscle sarcomeres, to several factors. (1) The
htAbs have exquisite specificity and affinity towards
cardiac myosin. Therefore, their exclusive targets are
molecules of myosin, which are present only in the
regions of the damaged cardiomyocytes. (2) Myosin
retains its antigenicity and accessibility to serve as a
solid anchoring scaffold. (3) The htAbs have high spe-
cificity towards CD34+, CD117+, and CD133+ stem
cells. Therefore, pure batches of stem cells are obtained
and presented to the infarcted myocardium. (4) The
anti-dsDNA and anti-PS are effective in eliminating all
dead and dying cells. Therefore, only viable cells, with
high differentiation potential, are administered. (5) The
model of therapy includes all the human-specific compo-
nents taken directly from the injured heart. Therefore,
they are thoroughly tested in the environment in vitro,
which is closest to the conditions in vivo.
Numbers of recruited cells may be reduced with time
due to dying or migration. The conditions in the in vitromodel of myocardial infarction included the patients’
infarcted tissue and serum; thus relatively thorough
simulation of the in vivo environment. The number of
retained and surviving cells was very high in this study.
Nevertheless, only in vivo trials, with active reticulo-
endothelial and immune systems, will provide validation
of this strategy in vivo in long term clinical trials.
The presented strategy consists of two elements: human
autologous bone marrow and htAbs. Using haBMSCs
reduces the problems associated with the immune re-
sponse, as well as with the iatrogenic injuries associated
with introducing immuno-suppression. However, the htAbs
may result in the immune response after multiple applica-
tions, if they are not produced by the patients’ own B cells.
We are vigorously working on resolving this problem.
We are also aware that the isolated cells may co-display
many other biomarkers, as a reflection of their differenti-
ation stages. As such, they may be featuring spectra of
regenerative potentials. Therefore, in the next task, we
are trying to identify most suitable sub-populations.
We are trying to accomplish this by multi-parameter,
magnetic or fluorescent sorting with the aid of the new,
bioengineered htAbs.
The results of this work also constitute the proof
of concept in vitro for directed differentiation, of the
selected populations of the human autologous bone
marrow stem cells into endothelium in situ - at the site
of therapeutic intervention.
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to generate endothelial progenitors from human induced
pluripotent stem cells and human embryonic stem cells,
which followed by advancing their differentiation into
endothelial cells, formation of tight junctions, migration
into the neighboring areas to reach other cell clusters,
and assembling into networks of endothelial cells. However,
one of the tests of pluripotency of induced and embryonic
stem cells is their ability to form teratomas in vivo [47-50].
This carries the risk of neoplasmic transformation, when
streamlined into the clinical setting. Although, methods
to safeguard therapeutic use of pluripotent stem cells
are being developed, the strategy proposed herein offers
an alternative worth pursuing.
Finally, if this strategy would be considered to become
a part of clinical trials, then all of the components would
have to be non-toxic for humans, have long shelf-life,
have controlled pharmacokinetics, and be manageable in
GMP environment. All factors introduced in this project
meet these requirements. They exerted their action, while
in the totally controlled environment, which contained all
the same human molecules and cells, which they would
be interacting with, in the in vivo first-in-man trials.
Conclusions
This novel strategy improved retention of the patients’
own bone marrow cells to the infarcted myocardia followed
by directed vasculogenesis. Therefore, it is worth pursuing
it in support of the ongoing clinical trials of cardiac regen-
erative medicine.
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